Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis | MicrobiomeTrials← Back to trialsNCT07503652
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-03Est. Completion: 2027-12
Enrollment target: 10 participants Locations- First Hospital of China Medical University, Shenyang, China
Other microbiome trials you might be interested in
Palmoplantar Pustulosis
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g co…
Fountain Valley, United StatesEst. completion Dec 14, 2026
Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants wi…
Birmingham, United StatesEst. completion Dec 27, 2027
Phase 3
Recruiting
Palmoplantar Pustulosis (PPP)
Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Curr…
Hangzhou, ChinaEst. completion Aug 1, 2028